Page 18 - Cll News Today

We take a look at the first FDA approval in the oncology space for 2024, the Lymphedema Treatment Act and more.

Researchers found that venetoclax, either alone or post treatment with a Bruton tyrosine kinase inhibitor (BTKi), was safe and effective for patients with chronic lymphocytic leukemia (CLL).

Abstracts from the 65th American Society of Hematology (ASH) Annual Meeting and Exposition provided new insight into multiple treatments for patients with multiple myeloma (MM), chronic lymphocytic leukemia (CLL), and follicular lymphoma (FL).

Experts explore the role of BTKi-based combination therapy in the front-line treatment of CLL, focusing on patient considerations and referencing key data from CAPTIVATE, FLAIR, MAJIC, and SEQUOIA (Arm D).

Faculty share insights into the overall strategy for managing relapsed/refractory CLL following first-line therapy with venetoclax-based regimens and BTK inhibitors, discussing strategy variations based on prior first-line treatments.

BTK degrader NX-5948 has been granted Fast Track designation by the FDA to treat some adults with relapsed or refractory chronic lymphocytic leukemia or relapsed or refractory small lymphocytic lymphoma.

Michael Choi, MD, discusses subsequent treatment options for patients with relapsed/refractory chronic lymphocytic leukemia who progressed or experienced unacceptable intolerance with a prior covalent BTK inhibitor.

Oncology experts discuss findings from ELEVATE-RR and outline key considerations for combination with acalabrutinib plus obinutuzumab.

Michael Choi, MD, discusses several key considerations for the treatment of chronic lymphocytic leukemia from his presentation at a recent OncLive® State of the Science Summit™ on hematologic malignancies.

Michael Choi, MD, discusses key mechanistic differences between BTK degraders and BTK inhibitors in the management of relapsed/refractory chronic lymphocytic leukemia, , as well as highlights how this approach could address unmet needs within the CLL treatment paradigm.